Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Madrigal Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Madrigal Pharmaceuticals, Inc.’s stock price such as:

• Madrigal Pharmaceuticals, Inc.’s current stock price and volume
• Why Madrigal Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for MDGL from analysts
• MDGL’s stock price momentum as measured by its relative strength

About Madrigal Pharmaceuticals, Inc. (MDGL)

Before we jump into Madrigal Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

Want to learn more about Madrigal Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of December 05, 2025, 4:00 PM, CST, Madrigal Pharmaceuticals, Inc.’s stock price was $577.300.

Madrigal Pharmaceuticals, Inc. is down 1.52% from its previous closing price of $586.210.

During the last market session, Madrigal Pharmaceuticals, Inc.’s stock traded between $573.000 and $593.000. Currently, there are approximately 22.48 million shares outstanding for Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Madrigal Pharmaceuticals, Inc. Stock Price History

Madrigal Pharmaceuticals, Inc.’s (MDGL) price is currently down 3.3% so far this month.

During the month of December, Madrigal Pharmaceuticals, Inc.’s stock price has reached a high of $598.770 and a low of $569.040.

Over the last year, Madrigal Pharmaceuticals, Inc. has hit prices as high as $605.000 and as low as $265.000. Year to date, Madrigal Pharmaceuticals, Inc.’s stock is up 87.09%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Madrigal Pharmaceuticals, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2025, there were 0 analysts who downgraded Madrigal Pharmaceuticals, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Madrigal Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Madrigal Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Madrigal Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Madrigal Pharmaceuticals, Inc. (MDGL) by visiting AAII Stock Evaluator.

Relative Price Strength of Madrigal Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2025, Madrigal Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 16.66%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Madrigal Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Madrigal Pharmaceuticals, Inc. Stock Price: Bottom Line

As of December 5, 2025, Madrigal Pharmaceuticals, Inc.’s stock price is $577.300, which is down 1.52% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Madrigal Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.